πŸ‡ΊπŸ‡Έ FDA
Patent

US 11207339

Targeted cancer therapy

granted A61KA61K31/7088A61K35/761

Quick answer

US patent 11207339 (Targeted cancer therapy) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K31/7088, A61K35/761, A61K35/763, A61K35/765